Ruifang An
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruifang An has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Kangsheng Liu
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
2 shared publicationsFeng Pan
Department of Andrology, State Key Laboratory of Reproductive Medicine, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China
1 shared publicationKangSheng Liu
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publicationMengjie Zhao
Department of Neuro-Psychiatric Institute, The Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, China
1 shared publicationShimin Wu
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
1 shared publicationXiangdong Wang
Department of Clinical Laboratory, Nanjing Chest Hospital, Medical School of Southeast University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 28 March 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-9
Detection of sperm DNA damage in male infertility patients and evaluation of Levocarnitine efficacy using sperm chromatin diffusion (SCD) and AI-DFI methods: a cross-sectional study
The objective of this study was to elucidate the relationship between sperm DNA damage and sperm parameters in male infertility patients and to assess the changes in sperm DNA fragmentation index before and after treatment with Levocarnitine in patients with asthenozoospermia and oligozoospermia. The results of 508 patients’ semen samples tested between August 2021 and December 2022 in our Department of Urology and Reproductive Medicine were retrospectively analyzed. The 508 patients were divided into 3 groups: normal semen group (n = 181), asthenozoospermia group (n = 170), and oligozoospermia group (n = 157). Their sperm DNA integrity was evaluated using the sperm chromatin diffusion (SCD) method and an artificial Intelligence-based DNA fragmentation index (AI-DFI). The patients were divided into two groups based on the assessment of sperm DNA integrity: a sperm DNA damage group and a sperm DNA integrity group. The two groups were then compared in terms of sperm concentration, motility, viability, and the proportion of normal sperm morphology. Pearson’s correlation coefficient analysis was employed to examine the relationship between sperm DNA damage and semen parameters. The results showed that sperm concentration, progressive motility, viability, and normal morphology rate were significantly lower in the DNA damaged group, and correlation analysis showed that the results of sperm DNA damage detection was negatively correlated with these semen parameters. And the DNA fragmentation index (DFI) was highest in the asthenozoospermia group, followed by the oligospermia group and the normal group, with significant differences between the groups (20.30 ± 2.85; 18.62 ± 2.42; 12.83 ± 2.13, P = 0.01). Treatment of patients in the group with sperm DNA damage with Levocarnitine oral solution was found to significantly improve sperm concentration, progressive motility, viability, normal morphology rate, and DFI results after its use (t = 7.265, 5.823, 7.750, 8.737, 8.355; P = 0.03, 0.02, 0.02, 0.03, 0.01). This study concludes that men with asthenozoospermia and oligozoospermia have a high DFI, and Levocarnitine is effective in reducing DNA damage and improving sperm quality, suggesting that Levocarnitine has potential for clinical use.
- 28 March 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-9
Open AccessDetection of sperm DNA damage in male infertility patients and evaluation of Levocarnitine efficacy using sperm chromatin diffusion (SCD) and AI-DFI methods: a cross-sectional study
The objective of this study was to elucidate the relationship between sperm DNA damage and sperm parameters in male infertility patients and to assess the changes in sperm DNA fragmentation index before and after treatment with Levocarnitine in patients with asthenozoospermia and oligozoospermia. The results of 508 patients’ semen samples tested between August 2021 and December 2022 in our Department of Urology and Reproductive Medicine were retrospectively analyzed. The 508 patients were divided into 3 groups: normal semen group (n = 181), asthenozoospermia group (n = 170), and oligozoospermia group (n = 157). Their sperm DNA integrity was evaluated using the sperm chromatin diffusion (SCD) method and an artificial Intelligence-based DNA fragmentation index (AI-DFI). The patients were divided into two groups based on the assessment of sperm DNA integrity: a sperm DNA damage group and a sperm DNA integrity group. The two groups were then compared in terms of sperm concentration, motility, viability, and the proportion of normal sperm morphology. Pearson’s correlation coefficient analysis was employed to examine the relationship between sperm DNA damage and semen parameters. The results showed that sperm concentration, progressive motility, viability, and normal morphology rate were significantly lower in the DNA damaged group, and correlation analysis showed that the results of sperm DNA damage detection was negatively correlated with these semen parameters. And the DNA fragmentation index (DFI) was highest in the asthenozoospermia group, followed by the oligospermia group and the normal group, with significant differences between the groups (20.30 ± 2.85; 18.62 ± 2.42; 12.83 ± 2.13, P = 0.01). Treatment of patients in the group with sperm DNA damage with Levocarnitine oral solution was found to significantly improve sperm concentration, progressive motility, viability, normal morphology rate, and DFI results after its use (t = 7.265, 5.823, 7.750, 8.737, 8.355; P = 0.03, 0.02, 0.02, 0.03, 0.01). This study concludes that men with asthenozoospermia and oligozoospermia have a high DFI, and Levocarnitine is effective in reducing DNA damage and improving sperm quality, suggesting that Levocarnitine has potential for clinical use.
- Open Access
- 17 December 2024
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 29 (12) , 416
The Mechanism and Clinical Significance of Sperm DNA Damage in Assisted Reproductive
The prevalence of sperm DNA fragmentation (SDF) is significantly higher in males with infertility, which is often associated with oligozoospermia and hypospermia. It can also occur in patients with infertility who have normal conventional semen indicators. The etiologies involve aberrations in sperm maturation, dysregulated apoptotic processes, and heightened levels of oxidative stress. In this article, we retrieved PubMed, China National Knowledge Infrastructure (CNKI) and Web of Science databases for articles and reviews published before February 28, 2024. Using “sperm DNA fragments; assisted reproductive technology, mechanism, clinical pregnancy outcome” as keywords, and comprehensively reviewed on their basis. Numerous literature sources have reported an increased utilization of SDF testing in the context of male infertility, as there is a negative correlation between SDF levels and the success of natural conception as well as assisted reproductive technologies. To enhance the clinical outcome for individuals experiencing infertility, investigating the prevalence and underlying mechanisms of sperm DNA damage is beneficial. This review article delves into the mechanisms that lead to sperm DNA damage and assesses the impact of DNA fragmentation index (DFI) on pregnancy outcomes in the context of assisted reproductive technologies.
- 17 December 2024
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 29 (12) , 416
Open AccessThe Mechanism and Clinical Significance of Sperm DNA Damage in Assisted Reproductive
The prevalence of sperm DNA fragmentation (SDF) is significantly higher in males with infertility, which is often associated with oligozoospermia and hypospermia. It can also occur in patients with infertility who have normal conventional semen indicators. The etiologies involve aberrations in sperm maturation, dysregulated apoptotic processes, and heightened levels of oxidative stress. In this article, we retrieved PubMed, China National Knowledge Infrastructure (CNKI) and Web of Science databases for articles and reviews published before February 28, 2024. Using “sperm DNA fragments; assisted reproductive technology, mechanism, clinical pregnancy outcome” as keywords, and comprehensively reviewed on their basis. Numerous literature sources have reported an increased utilization of SDF testing in the context of male infertility, as there is a negative correlation between SDF levels and the success of natural conception as well as assisted reproductive technologies. To enhance the clinical outcome for individuals experiencing infertility, investigating the prevalence and underlying mechanisms of sperm DNA damage is beneficial. This review article delves into the mechanisms that lead to sperm DNA damage and assesses the impact of DNA fragmentation index (DFI) on pregnancy outcomes in the context of assisted reproductive technologies.
- Top Cited PapersOpen Access
- 15 February 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Correlation analysis of sperm DNA fragmentation index with semen parameters and the effect of sperm DFI on outcomes of ART
Routine semen analysis provides limited information about a man’s male reproductive potential and can not always fully explain male infertility. Many male infertilities are caused by sperm DNA defects that routine semen quality analyses fail to detect. In this study, we analyzed the association of sperm DNA fragmentation index (DFI) with the semen routine, sperm morphology, in vitro fertilization embryo transfer (IVF-ET)/intracytoplasmic sperm injection (ICSI). Further, we explored the predictive value of sperm DFI in evaluating male fertility and the outcome of IVF-ET/ICSI. Data on sperm DFI, sperm routine, and sperm morphology were collected from 1462 males with infertility. According to DFI levels, there were 468 cases in group I (DFI ≤ 15%), 518 cases in group II (15% < DFI < 30%), and 476 cases in group III (DFI ≥ 30%). The correlations of sperm DFI with semen routine and malformation rate were analyzed. Seminal plasma malondialdehyde (MDA), and total antioxidant capacity (TAC) were assessed. Sperm DFI, semen routine, and sperm morphology were detected in male patients of 101 pairs of IVF-ET/ICSI infertile couples and subdivided into IVF-I group (DFI ≤ 15%), IVF-II group (15% < DFI < 30%), IVF-III group (DFI ≥ 30%), ICSI-I group (DFI ≤ 15%), ICSI-II group (15% < DFI < 30%) and ICSI-III group (DFI ≥ 30%) according to DFI value. The effect of sperm DFI on the outcome of IVF-ET/ICSI was analyzed. There were significant differences in sperm survival rate, sperm concentration, and PR% between groupIII and group II (P < 0.01). There were significant differences in sperm survival rate, sperm concentration and PR% between group III and group I (P < 0.01). There was no significant difference in semen volume, age, abstinence days, or percentage of normal sperm between the three groups (P > 0.05). DFI was positively correlated with MDA content ( P < 0.01) and negatively correlated with TAC (P < 0.01). Sperm DFI was negatively correlated with sperm survival rate, sperm concentration, and PR% (P < 0.01). There was no correlation with age, abstinence days, semen volume, or percentage of normal-form sperm (r = 0.16, 0.05, 0.04, -0.18, p > 0.05). Compared with IVF-I group, the sperm concentration and PR were decreased in IVF-III group. The sperm malformation rate was higher in IVF-III group than that in IVF-II group. Comparatively, the PR was decreased in ICSI-III group. The sperm malformation rate was higher in ICSI-III group than that of the ICSI-I group (P < 0.05). There were no statistically significant differences in fertilization rate, cleavage rate, embryo rate, and clinical pregnancy rate between IVF group or ICSI group, and between all subgroups (P > 0.05). Sperm DFI is negatively associated with sperm survival rate, sperm concentration, and PR%. Antioxidants can decrease the rate of DNA fragmentation. Sperm DFI has proven to be very valuable in the male fertility evaluation, but its significance as a predictor of pregnancy outcomes following assisted reproductive technology. (ART) requires further investigation.
- 15 February 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Top Cited PapersOpen AccessCorrelation analysis of sperm DNA fragmentation index with semen parameters and the effect of sperm DFI on outcomes of ART
Routine semen analysis provides limited information about a man’s male reproductive potential and can not always fully explain male infertility. Many male infertilities are caused by sperm DNA defects that routine semen quality analyses fail to detect. In this study, we analyzed the association of sperm DNA fragmentation index (DFI) with the semen routine, sperm morphology, in vitro fertilization embryo transfer (IVF-ET)/intracytoplasmic sperm injection (ICSI). Further, we explored the predictive value of sperm DFI in evaluating male fertility and the outcome of IVF-ET/ICSI. Data on sperm DFI, sperm routine, and sperm morphology were collected from 1462 males with infertility. According to DFI levels, there were 468 cases in group I (DFI ≤ 15%), 518 cases in group II (15% < DFI < 30%), and 476 cases in group III (DFI ≥ 30%). The correlations of sperm DFI with semen routine and malformation rate were analyzed. Seminal plasma malondialdehyde (MDA), and total antioxidant capacity (TAC) were assessed. Sperm DFI, semen routine, and sperm morphology were detected in male patients of 101 pairs of IVF-ET/ICSI infertile couples and subdivided into IVF-I group (DFI ≤ 15%), IVF-II group (15% < DFI < 30%), IVF-III group (DFI ≥ 30%), ICSI-I group (DFI ≤ 15%), ICSI-II group (15% < DFI < 30%) and ICSI-III group (DFI ≥ 30%) according to DFI value. The effect of sperm DFI on the outcome of IVF-ET/ICSI was analyzed. There were significant differences in sperm survival rate, sperm concentration, and PR% between groupIII and group II (P < 0.01). There were significant differences in sperm survival rate, sperm concentration and PR% between group III and group I (P < 0.01). There was no significant difference in semen volume, age, abstinence days, or percentage of normal sperm between the three groups (P > 0.05). DFI was positively correlated with MDA content ( P < 0.01) and negatively correlated with TAC (P < 0.01). Sperm DFI was negatively correlated with sperm survival rate, sperm concentration, and PR% (P < 0.01). There was no correlation with age, abstinence days, semen volume, or percentage of normal-form sperm (r = 0.16, 0.05, 0.04, -0.18, p > 0.05). Compared with IVF-I group, the sperm concentration and PR were decreased in IVF-III group. The sperm malformation rate was higher in IVF-III group than that in IVF-II group. Comparatively, the PR was decreased in ICSI-III group. The sperm malformation rate was higher in ICSI-III group than that of the ICSI-I group (P < 0.05). There were no statistically significant differences in fertilization rate, cleavage rate, embryo rate, and clinical pregnancy rate between IVF group or ICSI group, and between all subgroups (P > 0.05). Sperm DFI is negatively associated with sperm survival rate, sperm concentration, and PR%. Antioxidants can decrease the rate of DNA fragmentation. Sperm DFI has proven to be very valuable in the male fertility evaluation, but its significance as a predictor of pregnancy outcomes following assisted reproductive technology. (ART) requires further investigation.